Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Allergic Rhinosinusitis Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00660829
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo, 0.15% Azelastine Hydrochloride
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Austin, Texas • New Braunfels, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

NCT01697956
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
BDP, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Long Beach, California • Stockbridge, Georgia • Plymouth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 1 Interventional

Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients

NCT00932256
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
STAHIST NDC #58407-536-01
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nasal Physiologic Reactivity of Nonallergic Rhinitics to Cold Air Provocation

NCT00415493
View directory record Official record
Conditions
Vasomotor Rhinitis
Interventions
Cold-dry air provocation, Warm-moist air provocation
Other
Lead sponsor
Associated Scientists to Help Minimize Allergies
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

NCT01378429
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
ciclesonide nasal aerosol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Costa Mesa, California • Stockbridge, Georgia • Normal, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jul 23, 2026, 10:34 PM EDT
Terminated No phase listed Observational

Evaluation and Long-Term Follow-Up of Patients With Allergic and Inflammatory Disorders

NCT00557895
View directory record Official record
Conditions
Allergy, Asthma, Allergic Rhinitis, Mastocytosis, Atopic Dermatitis, Food Allergy
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 80 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 23, 2026, 10:34 PM EDT
Completed No phase listed Observational

Assessing Risk of Food Insecurity Within Households of Children With Food Allergy

NCT01897506
View directory record Official record
Conditions
Food Allergy, Asthma, Allergic Rhinitis, Atopic Dermatitis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
1 Year to 17 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2018 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using mEECs™

NCT02582073
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo (0.5ml), Placebo (1.0ml), Grass MATA MPL (0.5ml) 5100SU, Grass MATA MPL (1.0ml) 10200SU, Grass MATA MPL (1.0ml) 18200SU, Grass MATA (0.5ml) 5100SU
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Jul 23, 2026, 10:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?

NCT05287841
View directory record Official record
Conditions
Nasal Obstruction, Septal Defect, Allergic Rhinitis, Nasal Polyps, Nasal Valve Collapse
Interventions
Batten batten graft, Septoplasty, Inferior Turbinate Reduction
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Poplar Bluff, Missouri • New York, New York • Staten Island, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).

NCT01451541
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
Ciclesonide nasal aerosol 37 mcg, ciclesonide nasal aerosol 74 mcg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
848 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
60
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Costa Mesa, California + 51 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2012 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Subcutaneous Immunotherapy for Mouse in Adults

NCT02532179
View directory record Official record
Conditions
Asthma, Perennial Allergic Rhinitis
Interventions
Mouse Allergenic Extract
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis

NCT01018862
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Azelastine hydrochloride nasal spray 0.15%, Azelastine hydrochloride nasal spray 0.10%, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
6 Years to 12 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
39
States / cities
Costa Mesa, California • Long Beach, California • Mission Viejo, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR

NCT02443805
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial, House Dust Mite Allergy
Interventions
300 IR, Placebo
Biological
Lead sponsor
Stallergenes Greer
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2019 · Synced Jul 23, 2026, 10:34 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests

NCT01989897
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
saline with 1mg/ml Histamine base, diluent, saline with HSA--phenol
Drug
Lead sponsor
Bryan Martin, DO
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)

NCT01134705
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol, Placebo Nasal Aerosol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
35
States / cities
Los Angeles, California • Mission Viejo, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Jul 23, 2026, 10:34 PM EDT
Not listed Phase 4 Interventional

Singulair Use in Non-Allergic Rhinitis Eosinophil Syndrome (NARES)

NCT00406094
View directory record Official record
Conditions
Rhinitis
Interventions
montelukast, placebo
Drug
Lead sponsor
Bernstein, Jonathan A., M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 15, 2009 · Synced Jul 23, 2026, 10:34 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Examination of the Role of Atrial Natriuretic Peptide Polymorphisms in Allergic Rhinitis and Asthma Severity

NCT00584051
View directory record Official record
Conditions
Asthma, Allergic Rhinitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 40 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device

NCT02146781
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
CryJ2-DNA-LAMP plasmid vaccine by intradermal injection, Saline Control
Biological · Other
Lead sponsor
Immunomic Therapeutics, Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02870205
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
43
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00719862
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Placebo nasal spray, 0.15% azelastine hydrochloride Nasal Spray
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older · Female only
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
34
States / cities
Huntington Beach, California • Long Beach, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Jul 23, 2026, 10:34 PM EDT
Completed No phase listed Observational

Validation of Laser Doppler Flowmetry to Identify Allergic Rhinitis Patients With Pharmacogenetic Alterations in Histamine Metabolism

NCT00362999
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
7 Years to 18 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 23, 2026, 10:34 PM EDT
Completed Phase 4 Interventional Results available

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

NCT01654536
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide nasal aerosol, ciclesonide nasal spray
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
737 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Jul 23, 2026, 10:34 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

NCT01577628
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Asthma, Food Allergies, Allergic Rhinitis
Interventions
Lipikar Balm AP
Drug
Lead sponsor
Cosmetique Active International
Industry
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Canton, Michigan • Fort Gratiot, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced Jul 23, 2026, 10:34 PM EDT